Literature DB >> 26553038

Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.

Brian Madajewski1, Michael A Boatman1, Gaurab Chakrabarti2, David A Boothman2, Erik A Bey1.   

Abstract

UNLABELLED: The fundamental role that NAD(P)H/quinone oxidoreductase 1 (NQO1) plays, in normal cells, as a cytoprotective enzyme guarding against stress induced by reactive oxygen species (ROS) is well documented. However, what is not known is whether the observed overexpression of NQO1 in neoplastic cells contributes to their survival. The current study discovered that depleting NQO1 expression in A549 and H292 lung adenocarcinoma cells caused an increase in ROS formation, inhibited anchorage-independent growth, increased anoikis sensitization, and decreased three-dimensional tumor spheroid invasion. These in vivo data further implicate tumor-NQO1 expression in a protumor survival role, because its depletion suppressed cell proliferation and decreased lung tumor xenograft growth. Finally, these data reveal an exploitable link between tumor-NQO1 expression and the survival of lung tumors because NQO1 depletion significantly decreased the percentage of ALDH((high)) cancer cells within the tumor population. IMPLICATIONS: Loss of tumor-NQO1 expression inhibits tumor growth and suggests that novel therapeutics directed at tumor-NQO1 may have clinical benefit. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26553038      PMCID: PMC4715967          DOI: 10.1158/1541-7786.MCR-15-0207-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  48 in total

Review 1.  Reactive oxygen species in cancer.

Authors:  Geou-Yarh Liou; Peter Storz
Journal:  Free Radic Res       Date:  2010-05

2.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.

Authors:  James P Sullivan; Monica Spinola; Michael Dodge; Maria G Raso; Carmen Behrens; Boning Gao; Katja Schuster; Chunli Shao; Jill E Larsen; Laura A Sullivan; Sofia Honorio; Yang Xie; Pier P Scaglioni; J Michael DiMaio; Adi F Gazdar; Jerry W Shay; Ignacio I Wistuba; John D Minna
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

Review 3.  Role of oxidative stress and DNA damage in human carcinogenesis.

Authors:  Thomas B Kryston; Anastassiya B Georgiev; Polycarpos Pissis; Alexandros G Georgakilas
Journal:  Mutat Res       Date:  2011-01-07       Impact factor: 2.433

4.  Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.

Authors:  Yasushi Matsuyama; Motoshi Suzuki; Chinatsu Arima; Qin Miao Huang; Shuta Tomida; Toshiyuki Takeuchi; Ryoji Sugiyama; Yasutomo Itoh; Yasushi Yatabe; Hidemi Goto; Takashi Takahashi
Journal:  Mol Carcinog       Date:  2011-04       Impact factor: 4.784

5.  High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer.

Authors:  Christel van den Hoogen; Geertje van der Horst; Henry Cheung; Jeroen T Buijs; Jenny M Lippitt; Natalia Guzmán-Ramírez; Freddie C Hamdy; Colby L Eaton; George N Thalmann; Marco G Cecchini; Rob C M Pelger; Gabri van der Pluijm
Journal:  Cancer Res       Date:  2010-06-01       Impact factor: 12.701

6.  The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.

Authors:  Jill M Kolesar; Suzanne E Dahlberg; Sharon Marsh; Howard L McLeod; David H Johnson; Steven M Keller; Joan H Schiller
Journal:  Oncol Rep       Date:  2011-04-06       Impact factor: 3.906

7.  Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.

Authors:  Long Shan Li; Erik A Bey; Ying Dong; Jieru Meng; Biswanath Patra; Jingsheng Yan; Xian-Jin Xie; Rolf A Brekken; Carlton C Barnett; William G Bornmann; Jinming Gao; David A Boothman
Journal:  Clin Cancer Res       Date:  2011-01-11       Impact factor: 13.801

Review 8.  Redox regulation in cancer: a double-edged sword with therapeutic potential.

Authors:  Asha Acharya; Ila Das; Des Chandhok; Tapas Saha
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

9.  Anchorage-independent cell growth signature identifies tumors with metastatic potential.

Authors:  S Mori; J T Chang; E R Andrechek; N Matsumura; T Baba; G Yao; J W Kim; M Gatza; S Murphy; J R Nevins
Journal:  Oncogene       Date:  2009-06-01       Impact factor: 9.867

10.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

Authors:  Gina M DeNicola; Florian A Karreth; Timothy J Humpton; Aarthi Gopinathan; Cong Wei; Kristopher Frese; Dipti Mangal; Kenneth H Yu; Charles J Yeo; Eric S Calhoun; Francesca Scrimieri; Jordan M Winter; Ralph H Hruban; Christine Iacobuzio-Donahue; Scott E Kern; Ian A Blair; David A Tuveson
Journal:  Nature       Date:  2011-07-06       Impact factor: 49.962

View more
  18 in total

1.  Grainyhead-like 2 Reverses the Metabolic Changes Induced by the Oncogenic Epithelial-Mesenchymal Transition: Effects on Anoikis.

Authors:  Joshua C Farris; Phillip M Pifer; Liang Zheng; Eyal Gottlieb; James Denvir; Steven M Frisch
Journal:  Mol Cancer Res       Date:  2016-04-15       Impact factor: 5.852

Review 2.  Oxidative Stress in Cancer.

Authors:  John D Hayes; Albena T Dinkova-Kostova; Kenneth D Tew
Journal:  Cancer Cell       Date:  2020-07-09       Impact factor: 31.743

Review 3.  Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment.

Authors:  Mark A Hawk; Zachary T Schafer
Journal:  J Biol Chem       Date:  2018-01-16       Impact factor: 5.157

4.  Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.

Authors:  Ganji Purnachandra Nagaraju; Batoul Farran; Matthew Farren; Gayathri Chalikonda; Christina Wu; Gregory B Lesinski; Bassel F El-Rayes
Journal:  Cancer       Date:  2020-05-08       Impact factor: 6.860

5.  NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.

Authors:  Manali Dimri; Ashley Humphries; Archana Laknaur; Sawsan Elattar; Tae Jin Lee; Ashok Sharma; Ravindra Kolhe; Ande Satyanarayana
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

6.  Role and mechanism of benzo[a]pyrene in the transformation of chronic obstructive pulmonary disease into lung adenocarcinoma.

Authors:  Lei Wang; Qi Chen; Tingting Liu; Tuya Bai; Mengdi Zhang; Yuxia Hu; Jun Li; Fuhou Chang
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-13       Impact factor: 4.322

7.  MiR-485-5p Suppress the Malignant Characteristics of the Lung Adenocarcinoma via Targeting NADPH Quinone Oxidoreductase-1 to Inhibit the PI3K/Akt.

Authors:  Yupeng Chen; Lin Wu; Min Bao
Journal:  Mol Biotechnol       Date:  2022-10-11       Impact factor: 2.860

Review 8.  Review on NAD(P)H dehydrogenase quinone 1 (NQO1) pathway.

Authors:  S Preethi; K Arthiga; Amit B Patil; Asha Spandana; Vikas Jain
Journal:  Mol Biol Rep       Date:  2022-03-28       Impact factor: 2.742

9.  Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.

Authors:  Muhammad Shaalan Beg; Xiumei Huang; Molly A Silvers; David E Gerber; Joyce Bolluyt; Venetia Sarode; Farjana Fattah; Ralph J Deberardinis; Matthew E Merritt; Xian-Jin Xie; Richard Leff; Daniel Laheru; David A Boothman
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 2.885

10.  The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.

Authors:  Molly A Silvers; Stanislaw Deja; Naveen Singh; Robert A Egnatchik; Jessica Sudderth; Xiuquan Luo; Muhammad S Beg; Shawn C Burgess; Ralph J DeBerardinis; David A Boothman; Matthew E Merritt
Journal:  J Biol Chem       Date:  2017-09-15       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.